Skip to main content

Miromatrix Medical Added to Russell Microcap® Index

Written by Customer Service on . Posted in Public Companies.

EDEN PRAIRIE, Minn., Sept. 20, 2021 (GLOBE NEWSWIRE) — Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients’ lives, today announced that the Company will be added to the Russell Microcap® Index, effective after the U.S. market opens today, September 20, 2021.

The Russell Microcap Index measures the microcap segment of the U.S. equity market, consisting of the smallest 1,000 securities in the small-cap Russell 2000® Index, plus the next 1,000 smallest eligible securities by market cap. The Index is completely reconstituted annually to ensure new and growing equities are reflected and companies continue to reflect appropriate capitalization and value characteristics.

“We are honored and thrilled to be a part of the Russell Microcap Index, and we believe the inclusion will increase our visibility and exposure with investors,” said Jeff Ross, Ph.D., Miromatrix CEO. “The inclusion in the Russell Microcap Index comes at an important time for Miromatrix, as we continue to advance our proprietary bioengineered organ technology towards submitting an IND with the FDA in the first half of 2022 for our Phase I Liver Assist Trial.”

Approximately $9 trillion in assets under management (AUM) are benchmarked to or invested in products based on the Russell US Indexes, underscoring the importance of reconstitution to investors and the markets. In addition, $16 trillion in assets are currently benchmarked to indexes offered by FTSE Russell.

For more information on the Russell Microcap® Index and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website.

About Miromatrix

Miromatrix Medical Inc. is a life sciences company pioneering a novel technology for bioengineering fully transplantable human organs to help save and improve patients’ lives. The Company has developed a proprietary perfusion technology platform for bioengineering organs that it believes will efficiently scale to address the shortage of available human organs. The Company’s initial development focus is on human livers and kidneys. For more information, visit miromatrix.com.

Investor Contact
Greg Chodaczek
347-620-7010
ir@miromatrix.com

Media Contact:
press@miromatrix.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.